A new genetic test called MammaPrint is helping many breast cancer patients. This test determines the risk of cancer ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, ...

UPPSALA, SE / ACCESS Newswire / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.